Table 4 Relation between anti-Toxoplasma IgG prevalence and clinical findings among patients (group 1)
From: Seroprevalence of Toxoplasma gondii among a group of Egyptian patients with type I diabetes mellitus
Anti-Toxoplasma IgG (seropositivity) | ||||||
|---|---|---|---|---|---|---|
Positive | Negative | χ 2 | p value | |||
No. | % | No. | % | |||
Retinopathy | ||||||
Yes | 12 | 44.4 | 14 | 42.4 | 0.02* | 0.88 |
No | 15 | 55.6 | 19 | 57.6 | ||
Nephropathy | ||||||
Yes | 2 | 7.4 | 1 | 3.0 | 0.599 | 0.58 |
No | 25 | 92.6 | 32 | 97.0 | ||
Neuropathy | ||||||
Yes | 4 | 14.8 | 4 | 12.1 | 0.09 | 1.0 |
No | 23 | 85.2 | 29 | 87.9 | ||
Liver disease | ||||||
Yes | 1 | 3.7 | 1 | 3.0 | 0.021* | 1.0 |
No | 26 | 96.3 | 32 | 97.0 | ||
Cancer | ||||||
Yes | 1 | 3.7 | 2 | 6.1 | 0.174 | 1.0 |
No | 26 | 96.3 | 31 | 93.9 | ||